trial
as of 2026-07-01A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCTId NCT06791122
at a glance
— · Active Not Recruiting
Enrollment 262 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2026-08-26
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Active Not Recruiting
Enrollment
262 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-01-23
Primary completion
2026-08-26
Eligibility
ALL · 18 Years
Interventions & indications
Indications
Sponsors
Boehringer IngelheimLead Sponsor
Sites
31 total
Imperial, United StatesLa Jolla, United StatesOceanside, United StatesOrange, United StatesOrange, United StatesStanford, United StatesTorrance, United StatesCromwell, United StatesHialeah, United StatesHialeah, United StatesMiami, United StatesMiami, United States
Facts & assertions
4 sourced
Enrollment
262
Phase
NA
Primary Completion Date
2026-08-26
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication